Functional gene studies have not been performed for CEP128, however mutations identified in refractory DLBCL patients, including those in CEP128, were associated with PI3K-Akt-mTOR signaling pathways and increased mitochondrial oxidative phosphorylation, and play an important role in treatment resistance [55]. The gene discussed is AKT1; the disease is diffuse large B-cell lymphoma.